All In Biotech

Drug Trial Radar · NCT05542576

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

Aug 24, 2022

Primary completion

Mar 15, 2023

Study completion Mar 15, 2023

Sponsor

Lead sponsor
Amydis Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).

Conditions

  • Parkinson Disease
  • Amyotrophic Lateral Sclerosis

Interventions

  • AMDX2011PDrug

    AMDX2011P single bolus injection intravenous for diagnostic review

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AMDX-2011P Adverse Events ProfileTime frame: 1 week

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Research Foundation

    Newport Beach, California

  • Brittany NIcholl

    Pasadena, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.